Clinical trial
Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia…
NCT00391287 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00391287 |
|---|---|
| Title | Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure |
| Official title | A Prospective, Immunogenicity Surveillance Registry (PRIMS) to Estimate the Incidence of Erythropoietin Antibody-Mediated Pure Red Cell Aplasia Among Subjects With Chronic Renal Failure and Subcutaneous Exposure to Recombinant Erythropoietin Products |
| Acronym | PRIMS |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Janssen-Cilag International NV Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Pure Red-Cell Aplasia, Chronic Kidney Failure |
| Enrollment | 15,334 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Oct 23, 2006 |
| Last update posted | Oct 3, 2014 |
| Countries | Australia, Belgium, Denmark, Finland, Germany, Greece, Ireland, Netherlands, Norway, Poland, Portugal, Spain and 3 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: